APA (7th ed.) Citation

Xu, X., Tang, L., Piao, X., Zhan, S., Chen, Y., & Feng, P. (2026). Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma. PLoS ONE, 21(5), 1. https://doi.org/10.1371/journal.pone.0349044

Chicago Style (17th ed.) Citation

Xu, XueYin, Lian Tang, XiangHua Piao, ShaoQing Zhan, Yong Chen, and PanFeng Feng. "Economic Evaluation of Finotonlimab Plus Bevacizumab as First-line Therapy for Advanced Hepatocellular Carcinoma." PLoS ONE 21, no. 5 (2026): 1. https://doi.org/10.1371/journal.pone.0349044.

MLA (9th ed.) Citation

Xu, XueYin, et al. "Economic Evaluation of Finotonlimab Plus Bevacizumab as First-line Therapy for Advanced Hepatocellular Carcinoma." PLoS ONE, vol. 21, no. 5, 2026, p. 1, https://doi.org/10.1371/journal.pone.0349044.